a a a


  1. Vergote, I. et al. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur. J. Cancer 69, 127–134 (2016).
  2. Hennessy, B. T. J. et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J. Clin. Oncol. 28, 3570–3576 (2010).
  3. Yates, M. et al. 884PD * Next generation sequencing of BRCA 1/2 in high grade ovarian tumors expands BRCA defects beyond germline mutations. Ann. Onc. 25, iv308- (2014).
  4. Pennington, K. P. et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20, 764 LP-775 (2014).
  5. Janavičius, R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J. 1, 397–412 (2010).
  6. Shanmughapriya, S., Nachiappan, V. & Natarajaseenivasan, K. BRCA1 and BRCA2 mutations in the ovarian cancer population across race and ethnicity: Special reference to Asia. Oncol. 84, 226–232 (2013).
  7. Balmaña, J., Díez, O., Rubio, I. T., Cardoso, F. & Group, O. behalf of the E. G. W. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann. Oncol. 22, vi31-vi34 (2011).
  8. Rhiem, K. et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res. 14, R156 (2012).
  9. Van der Kolk, L. et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families. Br Can Res and Treat. 124, 643-651 (2010).
  10. Tai, Y. C., Domchek, S., Parmigiani, G. & Chen, S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 99, 1811–1814 (2007).
  11. Cavanagh, H. et al. The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered Cancer Clin Pract. 13, 16 (2015).
  12. Klein, A. et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64, 2634-2638 (2004).
  13. Bell, D. et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
  14. https://www.kanker.nl/kankersoorten/prostaatkanker/algemeen/wat-is-prostaatkanker#show-menu, datum van raadpleging: 23 december 2022
  15. https://iknl.nl/kankersoorten/prostaatkanker/registratie/incidentie, datum van raadpleging: 23 december 2022
  16. https://iknl.nl/kankersoorten/prostaatkanker/registratie/incidentie, 23 datum van raadpleging: december 2022
  17. https://www.borstkanker.nl/nieuws/prostaatkankerscreening-voor-mannen-met-brca2-mutatie, datum van raadpleging: december 2022

Andere pagina's op BRCA-Mutatie.nl.